Highlights Biostar Pharmaceuticals, Inc.

Equities

BSPM

US0906783016

Market Closed - OTC Markets Other stock markets 12:22:33 31/05/2024 am IST			5-day change	1st Jan Change
0.000014 ^USD	-86.00%		-.--%	-86.00%

2023	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI
2023	Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	15/23/15	CI
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	12/23/12	CI
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.	02/19/02	CI
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.	02/18/02	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	21/17/21	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	16/17/16	CI
Biostar Pharmaceuticals Seeks Acquisitions	15/17/15	CI
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd.	07/17/07	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	20/17/20	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016	14/17/14	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	22/16/22	CI
Biostar Pharmaceuticals, Inc. to Launch New Product Aimed at Treating Effects of Rhinitis and Sinusitis	11/16/11	CI
Biostar Pharmaceuticals, Inc. executed a non-binding letter of intent to acquire Xianyang Yongsheng Health Products Co., Ltd.	22/16/22	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	23/16/23	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016	24/16/24	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2015	15/16/15	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2015	24/15/24	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results of the Second Quarter and Six Months Ended June 30, 2015	20/15/20	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	16/15/16	CI
Biostar Pharmaceuticals Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014	16/15/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biostar Pharmaceuticals, Inc.

Equities

BSPM

US0906783016

Highlights

Filters